Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionexus Gene Lab Corp. on June 17, 2025. The registrant is incorporated in Wyoming and trades on The Nasdaq Stock Market LLC under the symbol BGLC. The filing primarily addresses a change in senior management.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel changes rather than financial performance data.
Material Changes
The material change reported is the appointment of a new Chief Financial Officer (CFO) and the concurrent departure of the acting CFO.
- Appointment: Ms. Chong Set Fui (Angeline) was appointed as Chief Financial Officer and Principal Financial Officer, effective immediately on June 17, 2025.
- Departure: Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer.
- Compensation: Ms. Chong will receive a monthly salary of RM15,000 (approximately USD $3,500) plus benefits including medical coverage, fuel allowance, and eligibility for discretionary bonuses.
Management Commentary and Risks
Ms. Chong brings over 25 years of senior financial leadership experience, including a tenure as CFO of Avillion Berhad from 2013 to November 2024. She is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA). The appointment was approved by the Board of Directors following review by the Nomination and Corporate Governance Committee and Compensation Committee. The Company has entered into an indemnification agreement with Ms. Chong governed by Wyoming law. No related party transactions or family relationships requiring disclosure were identified.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 17, 2025).
- Review the attached Service Contract (Exhibit 10.7) for full terms of employment and bonus structures.
- Confirm the cessation of Mr. Su-Leng Tan Lee's duties as acting CFO.
- Check for any subsequent filings regarding the new CFO's impact on internal controls or financial reporting timelines.